Clinical trial of VDA-1102 ointment for patients with actinic keratosis

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Vidac Pharma Ltd.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Skin and Connective Tissue Diseases [C17]

Trial duration

11 Feb 2026 → ongoing

Decision date (initial)

2025-11-03

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Vidac Pharma Ltd.

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Therapy, Safety

To evaluate the efficacy of VDA-1102 ointment compared with placebo ointment on a predefined marker lesion after a treatment period of 12 weeks, assessed by LC-OCT.

Secondary objectives 3

1. To evaluate the efficacy of treatment VDA-1102 ointment compared with placebo ointment on a predefined marker lesion after a treatment period of 12 weeks, assessed by (immuno-) histological examination of a biopsy (optional).
2. To evaluate the clinical efficacy of treatment with VDA-1102 ointment compared with placebo on the AK lesions.
3. To evaluate the safety profile of treatment with VDA-1102 ointment compared with placebo.

Conditions and MedDRA coding

Actinic keratosis

Study design 1 period

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 8

1. Written informed consent prior to any study-related measure.
2. Male, female, diverse patients aged 18 years or older.
3. Clinically confirmed diagnosis of AK of the face or scalp.
4. AKASI (Actinic Keratosis Area and Severity Index) of at least 3.0.
5. Minimum of one AK lesion with a PRO score ≥ 2 on scalp or face, as assessed by LC-OCT at Visit 1.
6. Among the AK lesions with the highest PRO, the investigator must be able to identify one AK lesion which is suitable to serve as marker lesion for the primary endpoint assessment.
7. The area around the defined marker lesion must contain 4 to 8 isolated AK lesions (counted including the marker lesion) and will be suitable to serve as study treatment area, i.e. no further exclusion criterion applies to this area.
8. Expected high patient compliance in applying the study medication and following the study instructions.

Exclusion criteria 20

1. Treatment area extends to either eyelids, lips, ears, or nose.
2. History of a genetic skin-cancer disorder (e.g., xeroderma pigmentosum) or invasive tumour in the treatment area (e.g., Merkel cell tumour, invasive SCC or suspected or diagnosed malignancy (recent or within the preceding 5 years) or BCC (basal cell carcinoma, within the preceding 2 years).
3. AK with Olsen grade III in the treatment area.
4. Clinically significant scars, or hyperpigmentation, or tattoo in the treatment area.
5. History or evidence of skin conditions other than AK likely to interfere with the study evaluations, e.g., eczema or unstable psoriasis.
6. Need for immunosuppressive or immunomodulating treatments (including systemic or topical agents applied to the treatment area, such as corticosteroids or calcineurin inhibitors) or other therapies against malignancy and other AK treatments (such as Imiquimod, 5FU or PDT).
7. Evidence of clinically significant or unstable medical conditions such as metastatic tumour or tumour with high probability of metastatic spread, heart failure (NYHA class III or higher), immunosuppressive disorder (e.g., HIV, status post organ transplantation), hematologic, hepatic, renal, neurologic or endocrine disorder, collagen-vascular disorder (e.g., cerebrovascular or other bleeding disorders), gastrointestinal disorder (e.g., active ulcera or history of recurrent peptic ulcera or haemorrhage).
8. Known allergy to lidocaine (applies only to patients who consented to have a biopsy).
9. Patients not willing to stop the use of skin care products in the treatment area during the treatment and follow-up period (i.e. the whole study duration).
10. Patients not willing to stop the use of make-up, coloured day care cremes, and sunscreens in the treatment area within 12 hours prior to any study visit.
11. Patients not willing to abstain from sunbathing (including solarium) or any outdoor activities with intensive sun exposure without taking appropriate measures to protect the treatment areas during the study.
12. Pregnant or breast-feeding patients.
13. Women of childbearing potential not willing to use a highly effective method of contraception (failure rate of less than 1% per year) during the interventional period of the study and 2 weeks thereafter.
14. Non-vasectomized male study participants with female partners of childbearing potential not willing to use a highly effective method of contraception (failure rate of less than 1% per year) during the interventional period of the study and two weeks thereafter.
15. Patients having participated in another clinical study (medical devices, or medicinal products) during the 4 weeks before inclusion into this clinical study.
16. Any previous randomization into this clinical study.
17. Any suspicion of current drug or alcohol abuse.
18. Institutionalization because of legal or regulatory order.
19. Dependency (as an employee or relative) to the sponsor/responsible CRO or investigator and investigational team.
20. Suspected poor compliance.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. The modified PRO score of the marker lesion assessed by LC-OCT after a treatment period of 12 weeks will serve as primary endpoint. The marker lesion will be defined as the AK lesion with the highest PRO score (basal proliferation score as assessed by LC-OCT prior to treatment start) on head or face of the study participant at study entry

Secondary endpoints 10

1. 1. Secondary efficacy endpoints: The clearance of budding (PRO II) and papillary sprouting (PRO III) of the marker lesion assessed by LC-OCT at week 12.
2. Histological assessment of the modified PRO score of the marker lesion after a treatment period of 12 weeks based on a biopsy (optional).
3. Number of visible or palpable AK lesions in the treatment area.
4. Complete clearance rate assessed by lesion count with complete clearance being defined as the complete disappearance of all visible or palpable AK lesions in the treatment area.
5. Partial clearance rate 75%. A partial clearance 75% is achieved if the number of clinically visible or palpable AK lesions in the treatment area is reduced by at least 75% but less than 100% compared with baseline
6. Assessment of cosmetic appearance after 12 weeks in comparison to Visit 1.
7. Study participants’ assessment of the test product in comparison to placebo at the end of treatment.
8. 2. Secondary safety endpoints: (Serious) adverse events.
9. Local Skin Reaction Scores.
10. Number of histologically confirmed squamous cell carcinoma (SCC) in the treatment area.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Vidac Pharma Ltd.

Sponsor organisation

Vidac Pharma Ltd.

Address

7 Prof. Hillel Ve-Khanan Oppenheimer

City

Rekhovot

Postcode

7670107

Country

Israel

Scientific contact point

Organisation

Vidac Pharma Ltd.

Contact name

Eyal Breitbart

Public contact point

Organisation

Vidac Pharma Ltd.

Contact name

Eyal Breitbart

Third parties 6

Locations

1 EU/EEA country · 1 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 6 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications